Shots:

• The EUA submission is based on an interim analysis of the P-III COMET-ICE study assessing VIR-7831 vs PBO for the early treatment of COVID-19 in 583 adults at high risk of hospitalization
• The study demonstrated an 85% reduction in hospitalization. Due to evidence of profound efficacy- IDMC recommended stopping the trial for further enrollment
• Preclinical data of VIR-7831 suggested that the mAB maintains its activity against emerging variants. Additionally- the companies will continue discussions with the EMA and other global regulators to make VIR-7831 available to patients with COVID-19 asap

­ Ref: GSK | Image: GSK